Eagle Pharmaceuticals (EGRX) Posts Mixed Q1 Results

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.36), $0.10 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Innovaro (INV) Misses Q2 EPS by 9c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c